20. SPC Xeljanz 1 mg/ml perorálny roztok. Databáza Európskej liekovej agentúry, ŠUKL. 2023.
21. Rogler G. Efficacy of JAK inhibitors in Crohn's Disease. J Crohns Colitis. 2020;14(Supplement_2):S746-S754.
22. van Rheenen PF, Aloi M, Assa A, et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis. 2021;171-194.
23. Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21:783-792.
24. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm Bowel Dis. 2014;20:1353-1360.
25. Shen JL, Zhou Z, Cao JS, et al. Biologic therapy for Crohn's disease over the last 3 decades. World J Clin Cases. 2022;10(2):594-606.
26. Kammermeier J, Morris MA, Garrick V, et al. BSPGHAN IBD Working Group. Management of Crohn's disease. Arch Dis Child. 2016;101:475-480.
27. Kolho KL, Ainamo A. Progress in the treatment and outcome of pediatric inflammatory bowel disease patients. Expert Rev Clin Immunol. 2016;12:1337-1345.
28. Grover Z, Burgess C, Muir R, et al. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease. J Crohns Colitis. 2016;10:1159-1164.
29. Grossi V, Hyams JS. The safety of treatment options for pediatric Crohn's disease. Expert Opin Drug Saf. 2016;15:1383-1390.
30. Nuti F, Civitelli F, Bloise S, et al. Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn's Disease Cohort. J Crohns Colitis. 2016;10:5-12.
31. Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16:891-903.
32. Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2015;(10):CD000067.
33. Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2014;(8):CD010233.
34. Stocco G, Cuzzoni E, De Iudicibus S, et al. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms. World J Gastroenterol. 2015;21:3571-3578.
35. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016;7:CD008870.
36. Moja L, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn´s disease. Aliment Pharmacol Ther. 2015;41(11):1055-1065.
37. Tromm A, Bunganič I, Tomsová E, et al. Budesonide 9 mg is at least as effective as mesalamine 4,5 g in patients with mildly to moderately active Crohn´s disease. Gastroenterology. 2011;140(2):425-434.
38. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn´s disease. Cochrane Database Syst. Rev. 2008;2:CD006792.
39. Sherlock ME, MacDonald JK, Griffiths AM, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;(10):CD007698.
40. Kuenzig ME, Rezaie A, Kaplan GG, et al. Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration. J Can Assoc Gastroenterol. 2018;1(4):159-173.
41. Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr. 2022;22(1):175.
42. Dignass A, Stoynov S, Dorofeyev AE, et al. Once versus three times daily dosing of oral budesonide for active Crohn´s disease: A double-blind, double-dummy, randomised trial. J Crohns Colitis. 2014;8(9):970-980.
43. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn´s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25.
44. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn´s disease: results from the CHARM study. Gastroenterol. 2008;135(5):1493-1499.
45. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn´s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99(1):91-96.
46. Calvet X, Panés J, Alfaro N, et al. Delphi consensus statement: Quality indicators for inflammatory bowel disease comprehensive care units. J Crohns Colitis. 2014;8(3):240-251.
47. Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front. Pediatr. 2022;10:852580.
48. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn´s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterol. 2014;147(3):618-627.
49. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn´s disease. N Eng J Med. 2016;375(20):1946-1960.
50. Kaenkumchorn T, Kesavan A. Dietary Management of Pediatric Inflammatory Bowel Disease. J Med Food. 2019;22(11):1092-1099.